Market Reports Center One Stop Market Research Shop
Cancer Diagnostics Device Market Share, Size, Price, Growth, Trends and Forecast 2016 – 2020
Technavio Announces the Publication of its Research Report – Global Cancer Diagnostic Devices Market 2016-2020 Technavio recognizes the following companies as the key players in the global cancer diagnostics devices market: Abbott Diagnostics, Agilent Technologies, BD, bioMérieux, Qiagen, and Roche Diagnostics. Other Prominent Vendors in the market are: Affymetrix, Ambry Genetics, Annoroad, Aviva Biosciences, Biochain, Bio-Rad, Cancer Genetics, Cepheid, CompanionDx, DiagnoCure, Epic Sciences, Epigenomics, Genomic Health, HalioDX, Hologic, Illumina, Myriad Genetics, Thermo Fisher Scientific, Ventana Medical Systems, and Vysis. Download Brochure now @ https://marketreportscenter.com/reports/313744/global-cancerdiagnostics-device-market-2016-2020 Commenting on the report, an analyst from Technavio’ s team said: “A trend which will definitely boost market growth is product approvals and launches. The significant focus on cancer diagnosis has led to the development of novel cancer diagnostic devices in the market. Many of these products have received approval from regulatory agencies such as the FDA and Health Canada. The availability of these advanced tests and associated diagnostic devices has allowed medical facilities to adopt them for cancer diagnosis. For instance, Beckman Coulter's VERIS molecular diagnostic system and VERIS human cytomegalovirus assay received CE mark approval in May 2014.” According to the report, a key growth driver is the demand for personalized medicines. Proteins and genes control and manage the biochemical functions of the body. Any defect in the structure of a particular protein or gene can lead to specific conditions and disorders. The production of personalized drugs depends on the identification and study of protein and gene expressions. These drugs are customized based on an individual's protein or genetic profiles. Personalized medicines have high demand in oncology therapy since conventional cancer drug therapies fail to achieve desired patient outcomes.